1. VENTILATOR-ASSOCIATED PNEUMONIA; MICROBIOLOGY, MULTIDRUG RESISTANCE IMPACT AND ASSOCIATED RISK FACTORS IN TERTIARY HOSPITALS SETTINGS.
- Author
-
Zubair, Saba, Ali, Huma, Zafar, Farya, Raza, Syed Faheem, Ashraf, Irfan, Warind, Javaid, Ejaz Beg, Anwer, Rizvi, Mehwish, Zaib-un-Nisa, Naqvi, Ghazala R., and Tariq, Anum
- Subjects
VENTILATOR-associated pneumonia ,MULTIDRUG resistance ,MICROBIOLOGY - Abstract
Background: Patients associated with VAP having mortality rates range from 20 to 50% and this may extend up to 70% when multi-resistant and invasive pathogens accountable for infection, however, VAP is also interrelated with noteworthy rate of morbidity, extended period of stay in ICU, protracted MV, and augmented hospitalization cost. Objectives: To review the risk factors, incidence and transience rate of mortality for ventilator-associated pneumonia. Design: Prospective and cross sectional way. Period: From April 2016 to December 2016. Setting: Different Tertiary Care Institutes of Karachi, Pakistan. Method: A structured data collection form was prepared to record the information and validated using spearman correlation coefficient and Cronbach's α value. Value of α = 0.902 and p = 0.913 have revealed the suitable degree of reliability and uniformity. Data was collected with respect to gender, age, antibiotic utilization record, and main diagnosis outcomes. Microbiological basis of ventilator-associated pneumonia was assessed using patient lab record for rate and seclusion of organism. Results: In this study a detail of significant virulence factor articulated by these microorganisms has been depicted. Statistically insignificant differences were observed among the groups with respect to clinical and demographic characteristics like mean age, gender, infection severity scores (SOFA, MODS, CPIS and APACHE II), immune status of patients and type of the cases including surgical or clinical scenario. 39.3% patients developed early onset while 60.6% of cohort was observed with late onset of VAP. Conclusion: The precise microbial source of VAP are numerous and diverse. The realistic challenge at the present time is to portray the authentic approximate of the clinical consequences associated with VAP. Henceforth such investigations may be supportive in origination of the most favorable institutional antimicrobial strategy to reduce the associated complications of this threat. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF